Pediatric exclusivity gets pitched to boards as free money: run a study, get six extra months of exclusivity, collect the revenue. The data tell a messier story. The same mechanism that blocks generic entry also blocks itself, gets litigated, gets denied, and occasionally hands a company the safety signal that ends up on its own label. This is the case for treating pediatric exclusivity as a risk to be managed, not a prize to be banked.
What Pediatric Exclusivity Actually Is
Short answer: Pediatric exclusivity is a six-month extension of an FDA marketing bar, granted under Section 505A of the Federal Food, Drug, and Cosmetic Act when a sponsor completes pediatric studies that fairly respond to an FDA Written Request. It does not extend a patent. It delays when FDA can approve a competitor’s application.
The mechanism dates to the Food and Drug Administration Modernization Act of 1997, which first authorized FDA to trade six months of exclusivity for pediatric data. The Best Pharmaceuticals for Children Act (BPCA) codified and expanded the program in 2002, and after several rounds of reauthorization Congress made it permanent [1][2]. Roughly 300 pediatric studies and label updates for more than 115 products came out of the program in its first decade [4].
The Written Request Is the Only Document That Matters
A sponsor cannot volunteer pediatric data and claim the reward. FDA has to ask first, in a formal Written Request (WR) that specifies the indications, age groups, trial design, and submission deadline. Meeting minutes, informal FDA correspondence, and Phase 4 commitments do not count [3]. Sponsors regularly go back to FDA to amend a Written Request’s scope or push a deadline. Public FDA letters show this happening routinely across major sponsors: Pfizer negotiated enrollment language on a Xeljanz (tofacitinib) Written Request in 2023, Vertex pushed back its ivacaftor study deadline from 2023 to 2025, and Amgen’s Onyx unit has amended the Kyprolis (carfilzomib) Written Request four times since 2015 [FDA WR letters]. Every amendment is a new date on which the six months can slip, shrink, or disappear.
Quick answer: does the drug have to work?
No. Exclusivity attaches whether the pediatric results are positive, negative, or inconclusive, as long as the studies were properly conducted and reported against the Written Request [3][2]. That single fact is also why the program draws so much criticism, and it is central to the vulnerability case below.
BPCA vs. PREA: The Carrot Next to the Stick
FDA runs two pediatric programs that get confused constantly. BPCA is voluntary: do the requested studies, get six months. The Pediatric Research Equity Act (PREA), enacted in 2003, is mandatory: certain new drugs and biologics must be studied in children as a condition of approval, with no exclusivity attached [3][4]. A sponsor can be simultaneously required to study a drug in children under PREA and separately incentivized to study a related population under a BPCA Written Request. FDA has proposed narrowing that overlap, discussed below, and that proposal alone could shrink the number of drugs eligible for the six-month reward.
How Six Months Attaches, and Why That Mechanism Is Where the Risk Lives
It Blocks Approval. It Does Not Extend the Patent
Pediatric exclusivity does not add six months to a patent’s term. It adds six months to the period during which FDA cannot approve an ANDA or 505(b)(2) application containing a Paragraph II certification (patent expired), a Paragraph III certification (patent expiration date acknowledged), or a Paragraph IV certification a court has found valid and infringed [14]. That distinction sounds technical. It is the reason pediatric exclusivity interacts so unpredictably with Hatch-Waxman litigation, since the six months rides on top of whatever certification status an ANDA happens to hold on the day the underlying patent expires, not on a fixed calendar date set at the time exclusivity is granted.
The Active-Moiety Rule: One Study Protects an Entire Franchise, Not Just the Product Studied
Exclusivity attaches to every approved formulation, dosage, and indication that shares the same active moiety as the studied product, not to the specific product studied. A federal court confirmed this reading in National Pharmaceutical Alliance v. Henney [14]. That is the feature drug makers like: a pediatric study on one indication of a molecule can extend exclusivity across an entire multi-billion-dollar franchise built on the same active ingredient. It is also a feature generic challengers have to model for every product in a sponsor’s portfolio, not just the one they are trying to copy, which raises the cost and complexity of freedom-to-operate analysis on any molecule with an active BPCA history.
The Nine-Month Cutoff and the 2007 Timing Fix
Early in the program’s history, sponsors sometimes submitted pediatric study reports close to the natural expiration of the underlying patent or exclusivity, creating a de facto delay while FDA determined whether the six months had been earned [3]. Congress closed that gap in 2007: FDA must now make its pediatric exclusivity determination at least nine months before the underlying exclusivity or patent would otherwise expire, and the agency has up to 180 days to make that call [3][14]. FDA’s own guidance to sponsors spells out the practical math: submit study reports at least fifteen months before the date you need protected, nine months for the statutory cutoff plus 180 days for FDA’s review clock [26]. Miss that window and the six months simply does not attach, regardless of how good the data are.
Written Request Timeline: How the Clock Actually Runs
Scope can be renegotiated later; deadlines regularly slip
Sponsor conducts studies
No requirement the results be positive
Negative or safety-signal data still counts, but can trigger labeling action
Study reports submitted
Must “fairly respond” to the WR
Must land at least 9 months before target exclusivity expires
FDA review
Up to 180 days to determine exclusivity is earned
Determination can still land after generics expected certainty
Exclusivity attaches
Blocks ANDA/505(b)(2) approval for 6 months
Only if 9+ months remained on underlying exclusivity when granted
The Failure Mode Nobody Models: Negative Pediatric Data
Case Study: Acadia’s Nuplazid and the Written Request FDA Had to Rewrite
In January 2025, FDA amended its long-running Written Request for Acadia Pharmaceuticals’ Nuplazid (pimavanserin). The reason: the exploratory proof-of-concept study for irritability associated with autism spectrum disorder came back negative, and FDA agreed to drop the two follow-on efficacy and safety studies that would have been built on top of it [25]. That is not a hypothetical risk. It is a live, recent example of a Written Request having to be rewritten mid-program because the underlying science did not cooperate, years into a commitment that started with a 2018 Written Request and had already been amended once before, in 2021 [25].
What happens to exclusivity if the study reads negative?
Exclusivity is not conditioned on efficacy, so a negative result does not automatically disqualify a sponsor. But a negative or inconclusive proof-of-concept study routinely forces FDA and the sponsor to renegotiate the rest of the Written Request, as in the Nuplazid case, which resets timelines, adds legal and regulatory cost, and pushes the program closer to the nine-month cutoff described above. A negative study is rarely fatal to exclusivity by itself. It is very often fatal to the schedule the sponsor built its exclusivity math around.
The Antidepressant Precedent: When the Study That Earns Six Months Also Earns a Black Box
The 2004 Meta-Analysis and the Nine-Drug Warning
The pediatric exclusivity program’s biggest structural risk played out across the SSRI and SNRI class in the early 2000s. Manufacturers ran FDA-requested pediatric depression trials to earn six months of exclusivity. FDA pooled the resulting trial data into a meta-analysis, reclassified the adverse event data using consistent criteria the original trials had not used, and concluded that antidepressant use increased suicidality risk in pediatric patients across the class [17]. In October 2004, FDA directed a black box warning onto nine antidepressants: citalopram, fluvoxamine, paroxetine, fluoxetine, sertraline, venlafaxine, mirtazapine, nefazodone, and bupropion [17][20]. Several of those same drugs had generated, or were in the process of generating, their pediatric exclusivity from the very trials that produced the safety signal [20].
The aftermath is still being studied two decades later. A 2023 systematic review in Health Affairs found that pediatric antidepressant use dropped sharply after the warning, mental health visits and depression diagnoses fell, and several studies linked the reduction in treatment to increases in psychotropic drug poisonings and completed suicides among youth, effects that appeared to spill over into young adults not directly targeted by the warning [18][24].
What This Means for a Written Request Decision Today
The lesson is not that pediatric studies are dangerous to run. It is that a Written Request obligates a sponsor to generate data it does not control the outcome of, on a population where FDA’s tolerance for a safety signal is lower than in adults, and where the agency has both the authority and, as of 2004, the demonstrated willingness to act on that signal at a class level. A commercial team modeling six months of incremental revenue against pediatric trial cost needs a second line item: the expected cost of a labeling action if the signal runs the wrong way. Most internal ROI models for pediatric exclusivity do not include one.
Litigation Risk: Pediatric Exclusivity Inside Paragraph IV Fights
Norvasc and the ‘303 Patent: How “Ironclad” Exclusivity Nearly Backfired on Pfizer
Pfizer’s Norvasc (amlodipine besylate) produced the case that defines how pediatric exclusivity behaves inside real litigation. Pfizer’s ‘303 patent was set to expire March 25, 2007, with pediatric exclusivity attached. On March 22, 2007, a Federal Circuit panel reversed a district court and held the patent invalid in Pfizer’s case against Apotex and Torpharm [15][18]. That created an odd standoff: the patent had technically expired, all pending ANDAs converted to Paragraph II certifications and became subject to Pfizer’s pediatric exclusivity, and yet the company that had just won its patent case in court could not immediately launch [14][15]. FDA had to issue a formal Letter Decision in April 2007 to sort out whether a prevailing ANDA applicant could be blocked by pediatric exclusivity attached to a patent that court had just invalidated. FDA concluded Congress did not intend pediatric exclusivity to block a winning Paragraph IV litigant once the court’s mandate issued, carving out a narrow exception to otherwise “ironclad” exclusivity [14]. Pfizer ultimately delisted the ‘303 patent, removing the exclusivity barrier entirely [14].
Mylan v. Thompson and Ranbaxy v. FDA: The Paragraph II Conversion Problem
Two other cases shape how this plays out. In Mylan Laboratories v. Thompson, the D.C. Circuit upheld FDA’s authority to administratively convert an ANDA’s certification to Paragraph II once the underlying patent expires, even without the applicant’s request [14]. Ranbaxy Laboratories v. FDA reached the same conclusion [14]. Both rulings matter because they determine whether an ANDA sponsor gets pulled into a pediatric exclusivity block automatically, without having done anything wrong, purely as a function of the calendar and FDA’s administrative practice.
Three Ways an ANDA Sponsor Can Beat an Attached Pediatric Exclusivity
Obtain a waiver directly from the brand sponsor, which the FDA Law Blog’s own review calls a highly unlikely outcome in practice [14].
Win a final, non-appealable court decision of invalidity or non-infringement before the exclusivity clock closes the window, as Apotex did against Pfizer.
Get the blocking patent delisted from the Orange Book, which is what ultimately resolved the Norvasc standoff [14].
Paragraph Certification vs. Pediatric Exclusivity Interaction
Certification
Meaning
Pediatric Exclusivity Effect
Paragraph II
Patent has expired
Six-month block still applies if exclusivity attached with 9+ months remaining
Paragraph III
Sponsor accepts a future patent expiration date
Six-month block applies from that date forward
Paragraph IV
Patent invalid, unenforceable, or not infringed
Blocks approval unless applicant wins a final court decision, per FDA’s 2007 Letter Decision
When FDA Says No: Amgen, Sensipar, and the Limits of Entitlement
Amgen v. FDA (2017): Suing the Agency Over a Denied Written Request
Doing the studies is not a guarantee. On May 22, 2017, FDA rejected Amgen’s request for pediatric exclusivity on cinacalcet hydrochloride (Sensipar/Mimpara). Amgen sued FDA in the D.C. District Court days later. Four generic manufacturers intervened to protect their own approval timelines, and in January 2018 the court granted summary judgment in part to each side, remanding the matter back to FDA to address whether its denial was consistent with a prior exclusivity decision on a different drug [12]. That is a sponsor that ran the studies, believed it had complied with its Written Request, and still ended up in federal court fighting FDA for the exclusivity it thought it had earned.
“Fairly Responds” Is a Legal Standard, Not a Formality
The statutory phrase governing whether studies qualify is that they “fairly respond” to the Written Request [3]. That phrase gets litigated, as Sensipar shows, and FDA’s application of it across different drugs has been challenged as inconsistent by the very companies asked to meet it [12]. A sponsor cannot treat compliance with a Written Request as a checkbox exercise. It is closer to a contested regulatory determination, complete with the possibility of an adverse decision, an appeal, and years of legal cost before the six months either attaches or evaporates.
Entresto’s 2025 Fire Drill: Pediatric Exclusivity as the Last Line of Defense
The ‘659 Patent, the MDL, and the July 2025 Expiration
Novartis’s Entresto (sacubitril/valsartan) shows what happens when pediatric exclusivity becomes the only thing standing between a blockbuster and generic entry. The composition patent covering the combination, the ‘659 patent, was set to expire January 15, 2025, with pediatric exclusivity running the date to July 15, 2025 [16]. Novartis had sued eighteen generic manufacturers in 2019 in what consolidated into multidistrict litigation in Delaware, In re: Entresto (Sacubitril/Valsartan) Patent Litigation. By 2025, MSN Pharmaceuticals was the last generic still contesting the patent. Novartis won a temporary injunction blocking MSN’s launch, and the Federal Circuit lifted that injunction on July 22, 2025, one week after the pediatric exclusivity period itself had run out on July 16 [16]. Multiple generics launched within days. MSN went on to petition the Supreme Court over how courts should treat after-arising technology in an invalidity analysis [16].
What the Entresto litigation teaches about racing the clock
Entresto is the modern version of the Norvasc problem. A brand sponsor can win an injunction, lose it, and watch the pediatric exclusivity date arrive in the middle of active appellate litigation, with the actual generic launch date determined by whichever event resolves last, not by the exclusivity calculation alone. For a $9-billion-plus franchise, a seven-day gap between the exclusivity expiration and the court’s final word was the entire remaining margin.
The Nexium Problem: Getting Tripped Up by an Exclusivity You Didn’t Know Was Live
Waivers Are the Generic Industry’s Only Reliable Exit Ramp
AstraZeneca’s Nexium (esomeprazole magnesium) generated cascading periods of pediatric exclusivity across multiple Orange Book-listed patents. Only one generic applicant, Ivax Pharmaceuticals, had an approved ANDA at the point the FDA Law Blog reviewed the situation, and Ivax got there only after securing a waiver of pediatric exclusivity directly from AstraZeneca [14]. Other ANDA sponsors on the same molecule were not as fortunate [14]. The lesson for competitive intelligence teams tracking generic entry dates: a patent expiration date on an Orange Book listing is not the whole story if pediatric exclusivity is layered on top, and that layering can differ ANDA by ANDA depending on who negotiated a waiver and who did not. This is precisely the kind of exclusivity-code and Written-Request tracking DrugPatentWatch’s product pages are built to surface before a generic launch date gets pinned to a calendar.
What Six Months Is Actually Worth, in Real Dollars
The 2013-2023 Data: 110 Drugs, $9.03 Billion, and a 36 Percent Hit Rate
A 2025 study in the Journal of Pediatrics tracked every pediatric exclusivity grant from 2013 through 2023: 229 clinical trials, 110 drugs granted exclusivity, new efficacy labeling for 97 percent of them and new safety labeling for 20 percent [19][29]. Only 40 of those 110 drugs, 36 percent, actually faced generic entry within the study window where the revenue effect could be measured [19].
“Median excess revenue attributable to the incentive was $133.8 million per exclusivity grant for a total of $9.03 billion” across the 40 drugs where generic entry occurred during the study period [19].
Exclusivity was typically granted a median of 2.34 years before generic entry actually happened, which means the value of any single grant depends heavily on unrelated variables, like how many companies eventually file Paragraph IV challenges and how that litigation resolves, not on the exclusivity grant itself [19].
The 2007-2012 Data: Plavix, Seroquel, Cymbalta, Prevacid
An earlier study covering 2007 through 2012 priced 54 drugs granted pediatric exclusivity. Total pediatric trial investment across those drugs ran $4.9 billion in 2017 dollars, against $29.0 billion in six-month gross revenue, a median additional revenue of $221.7 million per drug [20]. Four drugs cleared $1 billion in additional revenue from the six-month extension alone: clopidogrel (Plavix) at $2.36 billion, quetiapine (Seroquel) at $1.44 billion, duloxetine (Cymbalta) at $1.36 billion, and lansoprazole (Prevacid) at $1.22 billion [20]. The smallest grant in the cohort, almotriptan (Axert), generated just $9.8 million in additional revenue [20], a reminder that the blockbuster outcomes get the headlines while a meaningful share of the cohort barely clears the cost of the trials that earned it.
Top Pediatric Exclusivity Revenue Grants, 2007-2012 Cohort
Drug
Active Ingredient
Additional Revenue
Plavix
Clopidogrel
$2.36 billion
Seroquel
Quetiapine
$1.44 billion
Cymbalta
Duloxetine
$1.36 billion
Prevacid
Lansoprazole
$1.22 billion
Axert
Almotriptan
$9.8 million
Source: [20]. Figures in 2017 dollars.
Why Congress Keeps Calling It a Windfall
BPCA itself required a Government Accountability Office cost-benefit study by October 2006, weighing added pediatric labeling value against higher Medicaid and payer expenditures, lost generic industry revenue, and delayed retail competition [32]. That mandated skepticism has never fully gone away. It is the reason the program’s critics describe it as a windfall rather than an incentive: the studies get done, the label gets updated, and the sponsor keeps the revenue difference even when, as in the majority of the 2013-2023 cohort, no generic entry ever occurred during the measurement window to test whether the exclusivity actually delayed anything [8][19].
Oncology Runs a Different Playbook
Sprycel, Halaven, Jakafi, and the Children’s Oncology Group
Pediatric oncology exclusivity has its own cost structure, largely because the Children’s Oncology Group (COG) runs many of the underlying trials cooperatively rather than each sponsor building a dedicated program from scratch. A 2024 cohort study tracking cancer drugs granted pediatric exclusivity between 2010 and mid-2023, using a 10 percent cost of capital and a 55 percent assumed market-share erosion rate during the exclusivity window, included dasatinib (Sprycel, Bristol Myers Squibb), eribulin (Halaven, Eisai), and ruxolitinib (Jakafi, Incyte) among its cohort [34]. The mechanics of the reward are identical to any other drug class. The trial infrastructure and cost base are not, which changes the ROI math oncology-focused sponsors should be running relative to a primary-care blockbuster.
The Ground Is Shifting: FDA’s 2023 Draft Guidance
No More Written Requests for Studies PREA Already Requires
FDA issued two draft guidances in 2023 covering PREA and BPCA compliance. The most consequential proposal: FDA would stop issuing Written Requests, and therefore stop granting pediatric exclusivity, for studies that a sponsor is already legally required to conduct under PREA [2][23][37]. Until now, sponsors have in some cases been able to get paid in exclusivity for pediatric work they had to do anyway. If finalized, that overlap closes.
What this means for pipeline planning through 2027
Any sponsor building a five-year exclusivity model around a PREA-required pediatric program that also assumes a BPCA reward on top of it needs a contingency plan. The draft guidance has not been finalized as of this writing, but the direction of travel is explicit, and pharmaceutical IP teams should treat the free overlap between PREA compliance and BPCA reward as a shrinking asset rather than a durable one.
Biosimilars Break the Mechanism: Pediatric Exclusivity Under the BPCIA
No Automatic Stay, No Mechanical Trigger
Everything above assumes small-molecule Hatch-Waxman mechanics: a 30-month stay triggered by a Paragraph IV notice, a fixed statutory relationship between certification type and exclusivity block. Biologics under the Biologics Price Competition and Innovation Act (BPCIA) do not work that way. Patent disputes between a reference product sponsor and a biosimilar applicant proceed through the multi-step “patent dance” the Supreme Court addressed in Amgen Inc. v. Sandoz Inc., and that process does not generate an automatic stay equivalent to Hatch-Waxman’s 30 months [13]. Pediatric exclusivity still attaches to biologics under BPCA, but sponsors and biosimilar challengers alike are working without the mechanical certainty that governs the small-molecule cases discussed above, which makes timing forecasts on biologics meaningfully harder to model.
A Risk Checklist Before You Request a Written Request
Model the nine-month cutoff against your actual underlying exclusivity or patent expiration date, not the date you expect to file, and build in the full 180-day FDA review window.
Price a negative or ambiguous result scenario separately from a positive one; Nuplazid shows a Written Request can be rewritten mid-program.
Run a labeling-action scenario alongside the revenue model, particularly for CNS, psychiatric, and other drug classes where a pediatric safety signal has historical precedent for triggering class-wide action.
Check every Orange Book patent tied to the active moiety, not just the one you are focused on, since exclusivity attaches moiety-wide.
If you are a generic or biosimilar challenger, do not treat a favorable Paragraph IV ruling as the end of the analysis; confirm whether a final, non-appealable mandate has issued before assuming pediatric exclusivity cannot still block approval.
For biologics, do not import Hatch-Waxman stay assumptions into a BPCIA timeline; the patent dance does not generate the same automatic block.
Key Takeaways
Pediatric exclusivity is a six-month block on FDA approving a competing application, not an extension of the patent itself, and it can attach or fail to attach based on timing details most revenue models never account for.
Exclusivity does not require positive results, but negative results, as with Acadia’s Nuplazid, routinely force a renegotiated Written Request and a reset timeline.
The pediatric trials that earn six months can also generate the safety data that triggers a labeling action, as happened with the 2004 antidepressant black box warning across nine drugs.
FDA can deny exclusivity even after a sponsor completes its studies, as Amgen learned with Sensipar in 2017, and that denial can end up litigated in federal court.
Real litigation, from Norvasc’s ‘303 patent fight to Entresto’s 2025 injunction battle, shows pediatric exclusivity interacting with Paragraph IV outcomes in ways that are resolved case by case, not by formula.
The revenue is real and sometimes enormous, up to $9.03 billion in aggregate excess revenue across just the 2013-2023 cohort that saw generic entry, but 64 percent of grants in that cohort never got tested against generic competition at all within the study window.
FDA’s 2023 draft guidance signals a narrower future program, specifically around Written Requests issued for studies PREA already requires.
FAQ
Does pediatric exclusivity apply automatically once a company completes FDA-requested studies?
No. FDA still has to determine the studies fairly respond to the Written Request, a determination that can be denied and litigated, as in Amgen’s 2017 case over Sensipar [12].
Can pediatric exclusivity be granted for a drug that failed its pediatric trial?
Exclusivity is not conditioned on positive results, but a failed proof-of-concept study, as with Nuplazid, commonly leads FDA and the sponsor to amend the remaining study requirements, which can delay or reshape the eventual grant [25].
Does pediatric exclusivity extend a patent’s expiration date?
No. It extends the period during which FDA cannot approve a competing ANDA or 505(b)(2) application; the underlying patent term is unaffected [14].
What happens if a generic company wins its patent litigation before pediatric exclusivity expires?
It depends on whether a final, non-appealable court mandate has issued. FDA’s 2007 Norvasc Letter Decision found that a prevailing Paragraph IV litigant is not blocked by pediatric exclusivity once its mandate issues, but the applicant is still subject to the exclusivity until that point [14].
Can a generic company get around pediatric exclusivity without winning in court?
The most reliable route is a direct waiver from the brand sponsor, as Ivax obtained from AstraZeneca on Nexium, though the FDA Law Blog’s review characterizes waivers as an uncommon outcome [14].
Does pediatric exclusivity cover every product a company sells with the same active ingredient?
Yes. It attaches to the active moiety across all approved formulations, dosages, and indications, not only the specific product studied, a reading confirmed in National Pharmaceutical Alliance v. Henney [14].
How much is pediatric exclusivity typically worth?
Highly variable. The 2007-2012 cohort’s median additional revenue was $221.7 million per drug, ranging from $9.8 million (Axert) to $2.36 billion (Plavix) [20]. The 2013-2023 cohort’s median was lower, at $133.8 million per grant among drugs that saw generic entry [19].
Is FDA planning to restrict the pediatric exclusivity program?
FDA’s 2023 draft guidance proposes ending Written Requests, and the resulting exclusivity, for pediatric studies already mandated under PREA, which would narrow the pool of drugs eligible for the six-month reward if finalized [2][23].
Does pediatric exclusivity work the same way for biosimilars as it does for generic drugs?
The exclusivity itself still attaches under BPCA, but the surrounding patent litigation process differs. BPCIA’s patent dance does not generate an automatic stay comparable to Hatch-Waxman’s 30-month stay, making biosimilar timing harder to forecast mechanically [13].
Why do pediatric studies sometimes produce safety warnings instead of just label expansions?
Pediatric populations can show adverse event patterns, such as the suicidality signal FDA identified across nine antidepressants in 2004, that were not apparent or not consistently measured in the adult trials that originally supported approval, meaning a Written Request can generate data the sponsor did not anticipate [17][20].
References
Institute of Medicine. (2012). Safe and effective medicines for children: Pediatric studies conducted under the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act. National Academies Press. https://www.ncbi.nlm.nih.gov/books/NBK202032/
Hogan Lovells. (2023). New FDA pediatric draft guidances include proposal that could limit pediatric exclusivity grants. https://www.hoganlovells.com/en/publications/new-fda-pediatric-draft-guidances-include-proposal-that-could-limit-pediatric-exclusivity-grants
U.S. Food and Drug Administration. Exclusivity: Which one is for me? (Rinku Patel, PharmD). https://www.fda.gov/media/135234/download
AgencyIQ by POLITICO. (2023). Seeking to accelerate pediatric drug development, FDA offers guidance on requirements of two pivotal laws. https://www.agencyiq.com/blog/seeking-to-accelerate-pediatric-drug-development-fda-offers-guidance-on-requirements-of-two-pivotal-laws/
Li, J. S., et al. (2007). Economic return of clinical trials performed under the pediatric exclusivity program. JAMA. https://pmc.ncbi.nlm.nih.gov/articles/PMC2773665/
Cephalon, Inc. Cephalon, Inc. granted six months of pediatric exclusivity for PROVIGIL. BioSpace/PRNewswire. https://www.biospace.com/cephalon-inc-granted-six-months-of-pediatric-exclusivity-for-provigil-r
Federal Register. (2005). Vol. 70, No. 61, notices regarding BPCA pediatric information dissemination. https://www.govinfo.gov/content/pkg/FR-2005-03-31/pdf/05-6404.pdf
DrugPatentWatch. Read the docket, beat the market: How litigation data tells you when a generic drug will launch. https://www.drugpatentwatch.com/blog/read-the-docket-beat-the-market-how-litigation-data-tells-you-when-a-generic-drug-will-launch/
DrugPatentWatch. The six-month windfall: Transforming pediatric exclusivity from regulatory hurdle to strategic asset. https://www.drugpatentwatch.com/blog/the-six-month-windfall-transforming-pediatric-exclusivity-from-regulatory-hurdle-to-strategic-asset/
DrugPatentWatch. Read the clock right: Mapping regulatory exclusivities for true generic drug entry timing. https://www.drugpatentwatch.com/blog/read-the-clock-right-mapping-regulatory-exclusivities-for-true-generic-drug-entry-timing/
Barr Laboratories, Inc. (2000). Form 10-K405/A, FY2000. U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/0000010081/000095012301502607/y49301e10-k405a.txt
Amgen Inc. (2017). Form 10-K, FY2017. U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/0000318154/000031815418000004/amgn-12312017x10k.htm
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. Lessons for biopharma from the battle of Entresto. https://www.fr.com/insights/thought-leadership/blogs/lessons-for-biopharma-from-the-battle-of-entresto/
Karst, K. R. (2015). Pediatric exclusivity: Amazingly powerful, essentially ironclad . . . and often overlooked. FDA Law Blog, Hyman, Phelps & McNamara, P.C. https://www.thefdalawblog.com/2015/07/pediatric-exclusivity-amazingly-powerful-essentially-ironclad-and-often-overlooked/
Pfizer Inc. (2007). Form 10-Q, Q1 FY2007. U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/0000078003/000007800307000108/q1-07pfe.pdf
Busch, S. H., et al. Pediatric depression treatment in the aftermath of the black box warning: Implications for prescription drug policy. https://pmc.ncbi.nlm.nih.gov/articles/PMC2768536/
American Medical Association Journal of Ethics. (2012). Antidepressants and the FDA’s black-box warning: Determining a rational public policy in the absence of sufficient evidence. https://journalofethics.ama-assn.org/article/antidepressants-and-fdas-black-box-warning-determining-rational-public-policy-absence-sufficient/2012-06
Lu, C. Y., et al. Intended and unintended outcomes after FDA pediatric antidepressant warnings: A systematic review. Health Affairs. https://www.healthaffairs.org/doi/10.1377/hlthaff.2023.00263
Liu, I. T. T., Raymakers, A. J. N., Sarpatwari, A., & Kesselheim, A. S. (2025). Pediatric exclusivity revenues and labeling changes, 2013-2023. The Journal of Pediatrics. https://www.jpeds.com/article/S0022-3476(25)00200-8/abstract
Labeling changes and costs for clinical trials performed under the US Food and Drug Administration pediatric exclusivity extension, 2007 to 2012. https://pmc.ncbi.nlm.nih.gov/articles/PMC6248195/
Pediatric exclusivity revenues for cancer drugs. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11555575/
Applied Clinical Trials Online. FDA, Congress spur pediatric drug development. https://www.appliedclinicaltrialsonline.com/view/fda-congress-spur-pediatric-drug-development
Covington & Burling LLP. (2023). FDA publishes draft guidance on pediatric drug development. https://www.cov.com/en/news-and-insights/insights/2023/05/fda-publishes-draft-guidance-on-pediatric-drug-development
U.S. Pharmacist. (2024). Youth suicides rise after FDA antidepressant black-box warning. https://www.uspharmacist.com/article/youth-suicides-rise-after-fda-antidepressant-blackbox-warning
U.S. Food and Drug Administration. (2025). Written Request Amendment 1, Nuplazid (pimavanserin), Acadia Pharmaceuticals Inc. https://www.fda.gov/media/191629/download
U.S. Food and Drug Administration. Written Request Amendment 1, NDA 205832/IND 129333. https://www.fda.gov/media/173202/download
PharmaLawGrp. (2024). New FDA draft guidance aims to limit pediatric exclusivity extension awards. https://www.pharmalawgrp.com/blog/20/new-fda-draft-guidance-aims-to-limit-pediatric-exclusivity-extension-awards/
